Zai LabZLAB +1.34%64 Earnings per Share (Diluted) is $-1.70 as of Mar. 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.25 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,166 Biotechnology companies, Zai Lab ranks better than 59.61% on this metric.
Zai Lab's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.50.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.70.
Zai Lab's EPS without NRI for the
three
months ended in Mar. 2026 was $-0.58.
Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.95.
During the past 3 years, the average EPS without NRIGrowth Rate was 23.80% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 18.90% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -16.00% per year.
During the past 11 years, Zai Lab's highest 3-Year average EPS without NRI Growth Rate was 31.60% per year. The lowest was -101.00% per year. And the median was -13.65% per year.
Zai Lab (NAS:ZLAB) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Zai Lab Earnings per Share (Diluted) Related Terms
Zai Lab Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Zai Lab's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZLAB vs STOK, ADMA, VRDN: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Zai Lab's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's PE Ratio distribution charts can be found below:
* The bar in red indicates where Zai Lab's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Zai Lab's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.70
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-1.70 mean?
Zai Lab (ZLAB) has a Earnings per Share (Diluted) of $-1.70 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Zai Lab and its competitors. According to the industry distribution chart, Zai Lab ranks #471 out of 1166 companies in the Biotechnology industry, placing it in the top 40.4%.
Is Zai Lab's Earnings per Share (Diluted) too high?
Zai Lab's current Earnings per Share (Diluted) is $-1.70. Based on the distribution chart, Zai Lab ranks #471 out of 1166 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's Earnings per Share (Diluted) compare to STOK and ADMA?
According to the Biotechnology industry distribution chart, Zai Lab ranks #471 out of 1166 companies for Earnings per Share (Diluted). This puts Zai Lab in the upper half of its industry. The industry median Earnings per Share (Diluted) is 16.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.65, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Zai Lab and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current Earnings per Share (Diluted) is $-1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.25, compared to a current price of $19.34 — trading 36.1% below its estimated fair value. The current Earnings per Share (Diluted) is $-1.70. Zai Lab's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Zai Lab (ZLAB), the current Earnings per Share (Diluted) is $-1.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (ZLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of $19.34 is trading 36.1% below its estimated GF Value™ of $30.25.
GuruFocus considers Zai Lab to be Possible Value Trap.
Key valuation signals for ZLAB:
Earnings per Share (Diluted): $-1.70
GF Value™: $30.25 vs. price of $19.34 (36.1% below fair value)
No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score
Get the complete analysis for ZLAB
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLAB has been successfully added to your 
